NN-9440 by Inversago Pharma for Metabolic Syndrome: Likelihood of Approval
NN-9440 is under clinical development by Inversago Pharma and currently in Phase II for Metabolic Syndrome. According to GlobalData, Phase II drugs for Metabolic Syndrome does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the NN-9440 LoA Report. Buy the report here.GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.NN-9440 overviewINV-202 is under development for the treatment of type I diabetes, asthma, pre-diabetes/impaired glucose tolerance, abdominal obesity, hypertriglyceridemia, diabetic nephropathy, type 2 diabetes, non-alcoholic steatohepatitis (NASH), obesity and metabolic syndrome. The drug candidates are administered through oral route. They act by targeting cannabinoid receptor 1 (CB1R).Inversago Pharma overviewInversago Pharma is a preclinical-stage biotech company. The company develops peripherally-restricted cannabinoid receptor 1, a G protein-coupled cannabinoid receptor that is encoded by the CNR1 gene for the treatment of Prader-Willi Syndrome, Type-1 Diabetes, obesity and other metabolic disorders such as non-alcoholic steatohepatitis. For a complete picture of NN-9440's drug-specific PTSR and LoA scores, buy the report here.
NN-9440 is under clinical development by Inversago Pharma and currently in Phase II for Metabolic Syndrome.
What's Your Reaction?
